Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$25.05
-$0.61(-2.20%)
At close: 4:00 PM EST
$25.05
-$0.61(-2.20%)
Day’s Range― - ―
52-Week Range$13.74 - $70.43
Previous CloseN/A
Volume4.28M
Average Volume (3M)16.01M
Market Cap
$7.60B
Enterprise Value$5.12K
Total Cash (Recent Filing)$750.88M
Total Debt (Recent Filing)$1.13B
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Aug 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding223,080,080
10 Day Avg. Volume11,667,719
30 Day Avg. Volume16,009,148
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$30.14Price Target Upside20.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.09
Revenue Forecast (FY)$2.89B
Bulls Say, Bears Say
Bulls Say
Revenue & Subscriber GrowthSustained top-line expansion and a large recurring subscriber base create predictability in revenue and unit economics. Nearly 2.6M subscribers and on‑track weight‑loss adds (>100k/month) support multi-month retention, recurring refill cadence, and durable revenue while new categories scale.
Cash Generation & LiquidityConsistent positive operating and free cash flow coupled with a large cash stockpile improves self‑funding for product expansion, international M&A and tech investments. Strong cash conversion reduces reliance on equity markets and underpins multi‑quarter strategic execution.
Strategic Product & International ExpansionRapid adoption of branded GLP‑1s, the Eucalyptus acquisition and AI/labs verticalization materially shift the business toward higher scale and differentiated capabilities. These moves expand addressable markets, local regulatory expertise and data network effects that can sustain growth over many quarters.
Bears Say
Elevated LeverageA materially higher leverage profile reduces financial flexibility and raises refinancing and covenant risk if growth or margins slow. Elevated debt increases fixed obligations versus prior low‑leverage years, making capital allocation and shock absorption more constrained over the medium term.
Margin Pressure From Strategic PivotShifting mix toward lower‑margin weight‑loss, labs and international offerings alongside shorter shipping cadences is likely to compress gross margins structurally. Even as volumes rise, margin recovery depends on operational scale and supply‑chain fixes and may take multiple quarters to materialize.
Capital Structure Complexity & Dilution RiskLarge convertible issuance and capped‑call structures add refinancing and dilution complexity. Conversion mechanics and future equity issuance could dilute shareholders, while new receivables financing and amended credit terms layer contingent obligations that complicate long‑term capital allocation choices.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was $13.74 and its highest was $70.43 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is $7.60B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 22 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on May 11, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of $0.025 by -$0.425.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 223,080,080 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of $0.025. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.14 (20.30% Upside)
$30.14 (20.30% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $342.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.30%
12-Months-Change
Fundamentals
Return on Equity
-2.48%
Trailing 12-Months
Asset Growth
154.24%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
HIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$30.14
▲(20.30% Upside)
Technical Analysis
Ownership Overview
5.21% Insiders
14.77% Mutual Funds
0.04% Other Institutional Investors
58.89% Public Companies and Individual Investors